Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
REGENXBIO is a clinical-stage gene therapy company developing NAV Technology Platform-based treatments for rare genetic diseases and oncology. The company operates through two primary channels: proprietary clinical programs (RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy) and a licensing business model where it out-licenses its AAV platform to partners including AbbVie, Biogen, and Novartis. With a $400M market cap, negative operating margins of -95%, and $100M annual cash burn, REGENXBIO is a high-risk development-stage biotech dependent on clinical trial outcomes and partnership economics.
REGENXBIO monetizes its proprietary AAV gene delivery platform through two mechanisms: (1) licensing NAV vectors to pharmaceutical companies for upfront fees, milestone payments, and royalties on future product sales, creating a capital-light revenue stream, and (2) developing proprietary gene therapies for high-value indications where it retains full commercial rights. The 88% gross margin reflects the high-margin nature of licensing IP, but the company burns cash developing its own pipeline. Revenue is lumpy and milestone-dependent, creating significant quarter-to-quarter volatility. The company's competitive advantage lies in its broad AAV serotype portfolio covering multiple tissue tropisms, though this IP faces expiration risks and competitive challenges from newer capsid engineering approaches.
RGX-314 Phase 2/3 clinical trial data readouts for wet age-related macular degeneration (primary proprietary asset with peak sales potential exceeding $1B)
New licensing deals or expanded partnerships with large pharma, particularly upfront payments and milestone structures
FDA regulatory decisions on Investigational New Drug applications and clinical trial design feedback for lead programs
Cash runway updates and financing events (equity raises, debt facilities) given $100M+ annual burn rate
Competitive developments in AAV gene therapy space, particularly from Spark Therapeutics, bluebird bio, and newer capsid engineering platforms
AAV gene therapy platform faces emerging competition from next-generation delivery modalities including lipid nanoparticles, exosomes, and engineered capsids with superior tissue targeting and reduced immunogenicity
Regulatory pathway uncertainty for gene therapies with FDA requiring longer-term safety follow-up (10-15 years) and potential for black box warnings related to immunogenicity, genotoxicity, or oncogenicity risks
Reimbursement challenges for ultra-high-cost gene therapies ($500K-$2M+ per patient) as payers demand outcomes-based contracts and real-world evidence, compressing commercial potential
Patent cliff risk as foundational AAV serotype patents expire 2028-2032, enabling biosimilar competition and eroding licensing revenue
Large-cap pharma developing in-house AAV capabilities (Novartis, Roche, Pfizer) reducing reliance on external licensing and shrinking addressable partnership market
Direct competition in wet AMD from established anti-VEGF therapies (Eylea, Lucentis) with proven safety profiles and from competitive gene therapy programs at Adverum, Regenacy, and Gyroscope
Technology leapfrogging risk from CRISPR-based in vivo gene editing platforms that could obsolete AAV delivery for certain indications
Cash runway of approximately 18-24 months at current burn rate creates near-term financing pressure, likely requiring equity raise in 2026-2027 that could be highly dilutive at depressed valuations
Concentration risk in licensing revenue from small number of partners (top 3 likely represent 70%+ of revenue), creating vulnerability to partnership terminations or delays
Minimal tangible asset base (primarily cash and IP) limits borrowing capacity and downside protection in distressed scenarios
low - Pre-revenue biotech with minimal direct GDP linkage. Clinical trial timelines and regulatory processes are largely insulated from economic cycles. However, severe recessions can impact: (1) pharma partners' willingness to sign new licensing deals or advance programs, (2) capital markets access for equity financing, and (3) M&A valuations if REGENXBIO becomes a takeout target. Patient enrollment can be affected by healthcare system stress during economic downturns.
Rising interest rates create significant headwinds for pre-revenue biotech through multiple channels: (1) higher discount rates compress NPV of future cash flows 5-10+ years out, directly impacting valuation multiples, (2) reduced investor risk appetite shifts capital away from speculative growth stocks toward safer yielding alternatives, (3) increased cost of capital for future debt financing if needed. The company's 2.38x current ratio provides liquidity buffer, but sustained rate increases typically correlate with 20-40% biotech sector multiple compression. Cash holdings (~$200M estimated) earn higher yields in rising rate environment, partially offsetting negative valuation impact.
Moderate - While REGENXBIO has 0.72x debt/equity (manageable leverage), credit conditions significantly impact: (1) ability to raise growth capital through convertible debt or credit facilities at reasonable terms, (2) pharmaceutical partners' financial health and willingness to fund collaborations during credit stress, (3) M&A market liquidity if company pursues strategic alternatives. Tightening credit spreads can force dilutive equity raises versus preferred debt financing. High-yield spreads above 500bps historically correlate with biotech financing freezes.
growth - High-risk, high-reward binary outcome profile attracts speculative growth investors and biotech specialists willing to underwrite clinical and regulatory risk for potential 3-5x returns on successful drug approval. The -95% operating margin and negative cash flow eliminate value and income investors. Recent 36% one-year return followed by -34% three-month decline demonstrates extreme volatility typical of clinical-stage names. Institutional ownership likely dominated by healthcare-focused hedge funds and venture capital rather than broad index funds. Momentum traders enter around data catalysts but lack sustained conviction.
high - Clinical-stage biotech with binary event risk (trial readouts can move stock 30-50% in single session). Implied volatility typically 60-80%+ ahead of data catalysts. Low float and limited analyst coverage amplify price swings. The -34% three-month drawdown reflects either negative clinical update, financing concerns, or sector rotation. Beta to XBI likely 1.3-1.5x, with idiosyncratic risk dominating systematic factors.